Nitrosamine Risk Assessment: FDA Requirements and Process Guide

Nitrosamine Risk Assessment: FDA Requirements and Process Guide

Key Takeaways

Regulatory Background: FDA Nitrosamine Guidance Timeline

Understanding the regulatory timeline is critical because FDA expectations have shifted substantially since the initial valsartan crisis. Each guidance iteration expanded scope and increased specificity.

Key FDA Guidance Documents

FDA's current guidance (Version 3.0, March 2023) requires risk assessments for any product where the drug substance, excipient, or manufacturing process introduces a vulnerability to nitrosamine formation. This includes products with:

• APIs containing secondary, tertiary, or quaternary amines
• Manufacturing processes using sodium nitrite or other nitrosating agents
• Contact with recycled solvents or recovered materials
• Degradation pathways that could generate amine intermediates
• Packaging or water sources with nitrite/nitrate contamination potential

EMA Parallel Requirements

The European Medicines Agency issued its own nitrosamine guidance via the Article 5(3) referral procedure. While aligned with FDA in principle, EMA timelines and expectations differ in several important ways:

The 6-Step Nitrosamine Risk Assessment Process

FDA's recommended risk assessment follows a structured 6-step process. Each step builds on the previous one and must be documented to withstand regulatory scrutiny.

Step 1: Identify Potential Nitrosamine Formation Pathways

The first step requires systematic identification of all potential sources of nitrosamines in the product lifecycle. This goes beyond the API manufacturing process.

Sources to evaluate:

Critical evaluation criteria:

For a nitrosamine to form, two conditions must be met simultaneously:

1. A nitrosatable amine (secondary amine, or tertiary/quaternary amine capable of dealkylation)
2. A nitrosating agent (nitrite, nitrous acid, NOx gases)

If either component is absent and documented as absent, the risk assessment can conclude low risk for that pathway — but the documentation must be explicit.

Step 2: Conduct Root Cause Analysis

Root cause analysis determines why nitrosamines might form and identifies the specific mechanism. FDA expects this analysis to address the chemical and process-level causes, not just whether amines and nitrites are present.

Root cause categories per FDA guidance:

1. Process-related root causes

- Use of sodium nitrite as a reagent or quenching agent

- Recycled solvents contaminated with amines or nitrites

- Cross-contamination from shared equipment

- Degradation of dimethylformamide (DMF) or dimethylacetamide (DMA) solvents

1. Material-related root causes

- Amine-containing APIs with trace nitrite contamination in excipients

- Nitrate-containing water used in granulation or coating

- Rubber stopper extractables in parenteral products

1. Degradation-related root causes

- Nitrosamine drug substance-related impurities (NDSRIs) formed from the drug substance itself

- Accelerated degradation under ICH stability conditions

- Photodegradation pathways generating amine intermediates

Step 3: Evaluate and Rank Risk

Risk ranking assigns a relative priority to each identified pathway based on probability of occurrence and severity of outcome. FDA does not prescribe a specific risk ranking tool, but expects a systematic, documented approach.

Recommended risk ranking framework:

Products ranked as medium or high risk require confirmatory testing. Low-risk products may not require testing if the risk assessment documentation is sufficiently thorough and scientifically justified.

Step 4: Conduct Confirmatory Testing

Confirmatory testing validates the conclusions of the risk assessment using analytical methods capable of detecting nitrosamines at levels below the acceptable intake limit.

Analytical method requirements:

Testing scope:

• Minimum 3 representative commercial batches
• Retention samples from stability programs (if available)
• Accelerated and long-term stability samples (to assess formation over time)
• Drug substance (API) and finished drug product tested separately

Step 5: Implement Control Strategy

If confirmatory testing detects nitrosamines or confirms a formation pathway, a nitrosamine control strategy must be implemented. Control strategies follow the hierarchy of controls:

1. Eliminate the root cause (preferred): Remove nitrosating agents from process, switch to nitrite-free excipients, replace amine-containing reagents
2. Process controls: Adjust pH, temperature, or reaction time to minimize formation; implement dedicated equipment
3. Purification steps: Add purification steps (washing, recrystallization, chromatography) to remove formed nitrosamines
4. Specification and testing: Set specifications at or below AI limits; implement batch release testing

Step 6: Ongoing Monitoring and Lifecycle Management

Risk assessment is not a one-time exercise. FDA expects ongoing monitoring and reassessment when changes occur.

Triggers for reassessment:

• Manufacturing process changes (new equipment, site transfer, new reagents)
• New supplier for API, starting materials, or excipients
• Changes to container closure system
• New regulatory intelligence (updated AI limits, new nitrosamine analytes)
• Stability data showing increasing nitrosamine levels over time
• Post-market adverse event signals

Acceptable Intake Limits for Specific Nitrosamines

FDA has established compound-specific acceptable intake (AI) limits based on carcinogenicity data. These limits are derived from TD50 values (the dose that causes tumors in 50% of test animals) using linear extrapolation to a 1-in-100,000 cancer risk over a lifetime of exposure.

FDA Acceptable Intake Limits (Current as of 2026)

AI limit derivation methodology:

The AI limits above are calculated using the following formula from FDA guidance:

Where:

• TD50 is the most potent carcinogenicity data from rodent studies
• 50 kg is the assumed human body weight
• 50,000 represents the safety factor for a 1-in-100,000 lifetime cancer risk

For nitrosamines without compound-specific carcinogenicity data, FDA applies the ICH M7 Threshold of Toxicological Concern (TTC) of 18 ng/day as the default AI limit. This conservative default is based on the cohort of concern — the most potent known carcinogens.

Less-Than-Lifetime Exposure Adjustments

For products not intended for continuous lifetime use, FDA permits adjusted AI limits based on duration of treatment per ICH M7 staged TTC:

CDER Expectations for Risk Assessment Documentation

FDA reviewers evaluate risk assessments against specific documentation standards. Incomplete or poorly organized assessments are a common source of Information Requests and review delays.

Required Documentation Elements

Common FDA Information Request Triggers

Based on publicly available FDA review correspondence, the most frequent deficiencies in nitrosamine risk assessments include:

1. Incomplete amine inventory: Failure to evaluate all excipients for amine content
2. No water assessment: Omitting nitrite/nitrate evaluation in process water
3. Generic risk statements: Stating "low risk" without compound-specific justification
4. Inadequate analytical sensitivity: LOQ above 30% of AI limit
5. Missing NDSRI evaluation: Not assessing whether the drug substance itself can form a nitrosamine
6. No stability assessment: Failing to evaluate nitrosamine formation during product shelf life

Nitrosamine Drug Substance-Related Impurities (NDSRIs)

NDSRIs represent a distinct and increasingly important category of nitrosamine risk. Unlike process-related nitrosamines (where external amines react with nitrosating agents), NDSRIs form when the drug substance itself undergoes nitrosation.

NDSRI Evaluation Framework

An NDSRI evaluation is required when the drug substance contains:

• A secondary amine functional group
• A tertiary amine capable of N-dealkylation to a secondary amine
• An amine group that could react with trace nitrite under formulation conditions

NDSRI risk assessment considerations:

Key Takeaways

References